Kura Oncology amends bylaws to update advance notice, quorum, indemnification provisions

Kura Oncology, Inc.

Updated advance notice: annual meeting date shift threshold extended to >70 days (previously 30) before alternative notice window applies.
Quorum threshold changed from majority of outstanding shares to majority of voting power; default approval changed to majority of votes cast.
Incorporated universal proxy rules (Rule 14a-19); limited shareholder nominations to number of directors to be elected, no substitute nominees.
Enhanced forum selection: Delaware federal courts as backup for state court actions; added exclusive forum for Securities Act claims.
Expanded mandatory indemnification for directors/officers to maximum extent allowed by law; added expense advancement procedures.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Kura Oncology, Inc.: The Board adopted amended and restated bylaws effective January 28, 2026, making numerous changes to stockholder meeting procedures, advance notice requirements, quorum and voting thresholds, and other governance provisions (effective 2026-01-28).

Change: bylaw amendment
Effective: 2026-01-28

Exact text from the filing

On January 28, 2026, the board of directors (the “Board”) of Kura Oncology, Inc. (the “Company”) adopted amended and restated bylaws of the Company (as amended and restated, the “A&R Bylaws”), effective as of such adoption date.

View on SEC.gov

Browse all governance changes →

Kura Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-029705

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.